Patupilone induced vascular disruption in orthotopic rodent tumor models detected by magnetic resonance imaging and interstitial fluid pressure

Clinical Cancer Research

Volumn 11, Issue 21, 2005, Pages 7773-7784

  Ferretti, Stephane ^a   Allegrini, Peter R ^a   O'Reilly, Terence ^a   Schnell, Christian ^a   Stumm, Michael ^a   Wartmann, Markus ^a   Wood, Jeanette ^a   McSheehy, Paul M J ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; EPOTHILONE B; GADOTERIC ACID; MICROTUBULE STABILIZING AGENT; NATURAL PRODUCT; SUPERPARAMAGNETIC IRON OXIDE; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BLOOD VESSEL INJURY; BREAST TUMOR; CANCER MODEL; CONTRAST ENHANCEMENT; CONTROLLED STUDY; CORRELATION ANALYSIS; DIFFUSION COEFFICIENT; DISEASE MARKER; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; EVALUATION; FEMALE; HISTOLOGY; IMAGE ENHANCEMENT; MELANOMA; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RAT; TISSUE PRESSURE; TUMOR BLOOD FLOW; TUMOR NECROSIS; TUMOR VASCULARIZATION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOOD VESSELS; CASPASE 3; CASPASES; CONTRAST MEDIA; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; EPOTHILONES; FEMALE; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MAGNETIC RESONANCE IMAGING; MELANOMA; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; PRESSURE; RATS; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 27744607653     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-1165     Document Type: Article

References (46)

1. Hoefle G, Steinmetz H, Bedorf N, Schomberg D, Gerth K, Reichenbach H. Epothilone A and B-novel 16-membered macrolides with cytotoxic activity: isolation, crystal structure, and conformation in solution. Angew Chem Int Ed Engl 1996;35:1567-9.
2. Buey RM, Diaz JF, Andreu JM, et al. Interaction of epothilone analogs with the paclitaxel binding site: relationship between binding affinity, mictotubule stabilization, and cytotoxicity. Chem Biol 2004;11:225-36.
3. Nettles JH, Li H, Cornett B, Krahn JM, Snyder JP, Downing KH. The binding mode of epothilone A on αβ-tubulin by electron crystallography. Science 2004;305:866-9.
4. Altmann KH, Wartmann M, O'Reilly T. Epothilones and related structures-a new class of microtubule inhibitors with potent in vivo antitumor activity. Biochem Biophys Acta Rev Cancer 2000;1470:M79-91.
5. Wartmann M, Altmann K-H. The Biology and Medicinal Chemistry of Epothilones. Curr Med Chem Anti-Canc Agents 2002;2:123-48.
6. Bollag DM, McQueney PA, Zhu J, et al. Epothilones, 3 new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res 1995;55:2325-33.
7. Broker LE, Huisman C, Span SW, Rodriguez JA, Kruyt FA, Giaccone G. Cathepsin B mediates caspase-independent cell death induced by microtubule stabilizing agents in non-small cell lung cancer cells. Cancer Res 2004;64:27-30.
8. Giannakakou P, Sackett DL, Kang YK. Paclitaxel-resistant human ovarian cancel cells have mutant β-tubulins that exhibit impaired paclitaxel-driven polymerization. J Biol Chem 1995;272:17118-25.
9. Thorpe PE. Vascular targeting agents as cancer chemotherapeutics. Clin Cancer Res 2004;10:415-27.
10. Bocci G, Nicholaou KC, Kerbel RS. Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective anti-angiogenic window for various drugs. Cancer Res 2002;62:6938-43.
11. Woltering EA, Lewis JM, Maxwell PJ IV, et al. Development of a novel in vitro human tissue-based angiogenesis assay to evaluate the effect of antiangiogenic drugs. Ann Surg 2003;237:790-8.
12. Goodin S, Kane MP, Rubin EH. Epothilones: mechanism of action and biologic activity. J Clin Oncol 2004;22:2015-25.
13. Pietras K, Stumm M, Hubert M, et al. Imatinib enhances the therapeutic index of epothilone B (EP0906) by a tumor-selective increase of drug uptake. Clin Cancer Res 2003;9:3779-87.
14. Rothermel J, Wartmann M, Chen T, Hohneker J. EP0906 (epothilone B): a promising novel microtubule stabilizer. Semin Oncol 2003;30Suppl 6:S51-5.
15. Brueggen J, Altmann K-H, Blum W, et al. Pharmacokinetics of EP0906 (epothilone B) in HCT-15 tumor bearing mice. Proceedings of the 93rd AACR; San Francisco, CA; 2002 Apr 6-10. p. 212.
16. O'Reilly T, Wartmann M, Maira S-M, et al. Patupilone (epothilone B, EP0906) and imatinib (STI571, Glivec®) in combination display enhanced antitumor activity in vivo against experimental rat C6 glioma. Cancer Chemother Pharmacol 2005;55:117-28.
17. Jain RK. Barriers to drug deliver in solid tumors. Sci Am 1994;271:58-65.
18. Brown JM, Giaccia AJ. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res 1998;58:1408-16.
19. Pietras K, Rubin K, Sjoblom T, et al. Inhibition of PDGF receptor signalling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res 2002;62:5476-84.
20. Salnikov AV, Iversen VV, Koisti M, et al. Lowering of tumor interstitial fluid pressure specifically augments efficacy of chemotherapy. FASEB J 2003;17:1756-8.
21. Kristjansen PE, Boucher Y, Jain RK. Dexamethasone reduces the interstitial fluid pressure in a human colon adenocarcinoma xenograft. Cancer Res 1993;53:4764-6.
22. Pietras K, Ostman A, Sjoquist M, et al. Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res 2001;61:2929-34.
23. Griffon-Etienne G, Boucher Y, Brekken C, Suit HD, Jain RK. Taxane-induced apoptosis decompresses blood vessels and lowers interstitial fluid pressure in solid tumors: clinical implications. Cancer Res 1999;59:3776-82.
24. Lee CG, Heijn M, di Tomaso E, et al. Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res 2000;60:5565-70.
25. Milosevic M, Fyles A, Hedley D, et al. Interstitial fluid pressure predicts survival in patients with cervix cancer independent of clinical prognostic factors and tumor oxygen measurements. Cancer Res 2001;61:6400-5.
26. Willett CG, Boucher Y, di Tomaso E, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004;10:145-7.
27. Taghian AG, Abi-Raad R, Assaad SI, et al. Paclitaxel decreases the interstitial fluid pressure and improves oxygenation in breast cancers in patients treated with neoadjuvant chemotherapy: clinical implications. J Clin Oncol 2005;23:1951-61.
28. Thiesse P, Ollivier L, Di Stefano-Louineau D, et al. Response rate accuracy in oncology trials: reasons for inter-observer variability. J Clin Oncol 1997;15:3507-14.
29. Stroobants S, Goeminne J, Seegers M, et al. 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). Eur J Cancer 2003;39:2012-20.
30. Gronland B, Hogdall C, Hilden J, Engelholm SA, Hogdall EV, Hansen HH. Should CA-125 response criteria be preferred to Response Evaluation Criteria in Solid Tumors (RECIST) for prognostication during second-line chemotherapy of ovarian carcinoma? J Clin Oncol 2004;22:4051-8.
31. Woude GF, Kelloff GJ, Ruddon RW, et al. Reanalysis of cancer drugs: old drugs, new tricks. Cancer Res 2004;10:3897-907.
32. Morgan B, Thomas AL, Drevs J, et al. Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J Clin Oncol 2003;21:3955-64.
33. Rudin M, McSheehy PMJ, Allegrini PR, et al. PTK787/ZK222584, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor, reduces uptake of the contrast agent GdDOTA by murine orthotopic B16/BL6 melanoma tumors and inhibits their growth in vivo. NMR Biomed 2005;18:308-21.
34. Dennie J, Mandeville JB, Boxerman JL, Packard SD, Rosen BR, Weisskoff RM. NMR imaging of changes in vascular morphology due to tumor angiogenesis. Magn Reson Med 1998;40:793-9.
35. Troprès I, Grimault S,Vaeth A, et al. Vessel size imaging. Magn Reson Med 2001;45:397-408.
36. McSheehy PMJ, Schnell C, Ferretti S, Allegrini PR, Wartmann M, Wood J. Epothilone B (EP0906) demonstrates anti-angiogenic and anti-metastatic activity in syngeneic rodent tumor models. Proceedings of the 94th AACR; Washington, DC; 2003 Jul 11-14. p. 538.
37. Preda A, Novikov V, Moglich M, et al. MRI monitoring of Avastin antiangiogenesis therapy using B22956/1, a new blood pool contrast agent, in an experimental model of human cancer. J Magn Reson Imaging 2004;20:865-73.
38. Maxwell RJ, Wilson J, Prise VE, et al. Evaluation of the anti-vascular effects of combretastatin in rodent tumors by dynamic contrast enhanced MRI. NMR Biomed 2002;15:89-98.
39. Robinson SP, McIntyre DJO, Checkley D, et al. Tumor dose response to the antivascular agent ZD6126 assessed by magnetic resonance imaging. Br J Cancer 2003;88:1592-7.
40. Leach MO, Brindle KM, Evelhoch JL, et al. The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations. Br J Cancer 2005;92:1599-610.
41. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 2001;7:987-9.
42. Kauppinen RA. Monitoring cytotoxic tumor treatment response by diffusion magnetic resonance imaging and proton spectroscopy. NMR Biomed 2002;15:6-17.
43. Milosevic M, Fyles A, Hedley D, Hill R. The human tumor microenvironment: invasive (needle) measurement of oxygen and interstitial fluid pressure. Semin Radiat Oncol 2004;14:249-58.
44. Rees J. Advances in magnetic resonance imaging of brain tumours. Curr Opin Neurol 2003;16:643-50.
45. Lahorte CM, Vanderheyden JL, Steinmetz N, Van de Wiele C, Dierckx RA, Siegers G. Apoptosis-detecting radioligands: current state of the art and future perspectives. Eur J Nucl Med Mol Imaging 2004;31:887-919.
46. McSheehy PMJ, Becquet M, Ferretti S, Brueggen J, Schweitzer A, Wartmann M. Optimisation of a pre-clinical dosing schedule for the novel epothilone analogue ABJ879 based on tumour interstitial fluid pressure modulation in rat mammary tumour models [abstract 526]. Proceedings of the 16th Symposium on Molecular Targets and Cancer Therapeutics; Geneva, Switzerland; 2004 Sep 28-Oct 1.